CARMENCITA LANEZ: Open Payments
NPI 1770643959 · HOPELAWN, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$5,690 in 181 payments from 15 companies in 2025. Trend: 2023 $12,374 · 2024 $8,053 · 2025 $5,690
Speaker / faculty: $3,150Food & beverage: $2,540
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 32 | $3,512 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 38 | $513 |
| Neurocrine BioSciences, Inc. | 25 | $416 |
| Otsuka America Pharmaceutical, Inc. | 14 | $213 |
| Lundbeck LLC | 17 | $199 |
| Alkermes, Inc. | 13 | $197 |
| Axsome Therapeutics, Inc. | 12 | $158 |
| Tris Pharma Inc | 7 | $112 |
| Supernus Pharmaceuticals, Inc. | 6 | $99 |
| E.R. Squibb & Sons, L.L.C. | 5 | $85 |
Products named: VRAYLAR, CAPLYTA, INGREZZA, REXULTI, Auvelity, ABILIFY MAINTENA, ARISTADA, Dyanavel XR.
Industry payments across NJ — which companies pay providers there.
